GLP-1 medications and PCOS weight loss: what TikTok gets wrong
Quick answer
The creator describes inconsistent GLP-1 dosing over seven months, with weeks-long gaps between injections, alongside poor dietary adherence, resulting in 40 pounds of weight regain. This pattern is consistent with documented pharmacokinetic and behavioral findings: GLP-1 receptor agonists require consistent administration to maintain appetite suppression and metabolic effects, and abrupt or irregular cessation accelerates weight regain. She is restarting on 15 mg compounded tirzepatide, which is not FDA-approved and carries different regulatory status than brand-name Zepbound or Mounjaro.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @lizdamyl actually say?
She said she gained 40 pounds over roughly seven months after stopping her GLP-1 medication consistently, skipping weeks at a time, eating poorly, and not hitting her protein targets. Her conclusion: "this is a tool to help you get where you need to be, but you need to make the lifestyle changes or else it's worthless." She's now restarting at 205 pounds on 15 mg of compounded tirzepatide from a telehealth provider called Ivean Health.
That's the core claim: weight regain after GLP-1 discontinuation or inconsistent use is real, predictable, and partly self-inflicted if you stop doing the behavioral work. She's owning it publicly, which is unusual and worth credit.
Does the science back this up?
Yes, and the data is uncomfortable for anyone who thought these medications were a permanent fix. The evidence on weight regain after GLP-1 cessation is consistent and significant.
The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest example: participants who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. A follow-up analysis of tirzepatide from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar patterns, with placebo-switchers regaining roughly half their lost weight within 52 weeks compared to those who continued treatment.
What @lizdamyl experienced, going weeks without doses and not maintaining dietary habits, would logically accelerate that regain. GLP-1 agonists work partly by suppressing appetite and slowing gastric emptying. Stop the drug intermittently and inconsistently, and you lose those effects without any stable baseline to fall back on.
What did she get wrong, or right?
She got the big picture right. The framing that GLP-1s are "a tool" and not a substitute for behavioral change is accurate and consistent with how endocrinologists and obesity medicine specialists talk about these medications in clinical practice.
Where it gets messier: she calls her medication "trisepitide," which appears to be a mispronunciation of tirzepatide. Minor, but worth flagging because medication name accuracy matters when millions of people are searching these terms online.
More importantly, she doesn't mention she's using a compounded version of tirzepatide. Compounded tirzepatide is not FDA-approved, and the FDA has stated that compounded drugs are not demonstrated to be safe, effective, or equivalent to their brand-name counterparts. FormBlends and any responsible platform will tell you: compounded is not the same as Zepbound or Mounjaro. Period. That distinction matters for safety and for setting realistic expectations.
- Her weight loss journey numbers are plausible and internally consistent.
- Her explanation of why she regained is honest and matches the pharmacology.
- She does not overclaim what the drug does or promise outcomes to viewers.
What should you actually know?
Weight regain after GLP-1 discontinuation is not a personal failure unique to her. It's a documented pharmacological reality. These medications appear to require ongoing use for sustained effect in most people, similar to how antihypertensives require continued use to control blood pressure.
The behavioral component she describes, protein intake, hydration, consistent dosing, is real. Research from Wilding et al. (2021, NEJM) on semaglutide showed that participants who combined the drug with lifestyle intervention retained more benefit. But lifestyle changes alone couldn't fully compensate for stopping the medication in most subjects.
If you're considering a GLP-1 medication, ask your prescriber directly: what happens if I stop? What's the plan long-term? And if you're getting compounded tirzepatide specifically, ask about the source, concentration, and what quality controls are in place. Those are not paranoid questions. They are standard ones.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 medications and PCOS weight loss: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 medications and PCOS weight loss: what TikTok gets wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes inconsistent GLP-1 dosing over seven months, with weeks-long gaps between injections, alongside poor dietary adherence, resulting in 40 pounds of weight regain.
FormBlends verdict
The creator describes inconsistent GLP-1 dosing over seven months, with weeks-long gaps between injections, alongside poor dietary adherence, resulting in 40 pounds of weight regain. This pattern is consistent with documented pharmacokinetic and behavioral findings: GLP-1 receptor agonists require consistent administration to maintain appetite suppression and metabolic effects, and abrupt or irregular cessation accelerates weight regain. She is restarting on 15 mg compounded tirzepatide, which is not FDA-approved and carries different regulatory status than brand-name Zepbound or Mounjaro.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes inconsistent GLP-1 dosing over seven months, with weeks-long gaps between injections, alongside poor dietary adherence, resulting in 40 pounds of weight regain. This pattern is consistent with documented pharmacokinetic and behavioral findings: GLP-1 receptor agonists require consistent administration to maintain appetite suppression and metabolic effects, and abrupt or irregular cessation accelerates weight regain. She is restarting on 15 mg compounded tirzepatide, which is not FDA-approved and carries different regulatory status than brand-name Zepbound or Mounjaro.
- The SURMOUNT-4 trial (2024, JAMA) found tirzepatide discontinuation led to regain of roughly half of all lost weight within one year, consistent with what this creator experienced.
- Compounded tirzepatide is not FDA-approved and has not been shown to be safe or equivalent to brand-name Zepbound or Mounjaro. These are legally and pharmacologically distinct products.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The SURMOUNT-4 trial (2024, JAMA) found tirzepatide discontinuation led to regain of roughly half of all lost weight within one year, consistent with what this creator experienced.
- Compounded tirzepatide is not FDA-approved and has not been shown to be safe or equivalent to brand-name Zepbound or Mounjaro. These are legally and pharmacologically distinct products.
- Skipping GLP-1 doses intermittently over weeks is not a medically supervised taper. It disrupts steady-state drug levels and removes the pharmacological appetite suppression the medication provides.
- STEP 4 trial data (Rubino et al., 2021, JAMA) showed participants who stopped semaglutide regained roughly two-thirds of their lost weight within 52 weeks, even those who had lost substantial amounts.
- Protein intake and hydration are legitimate behavioral factors in GLP-1 outcomes, but they cannot fully compensate for medication gaps. Behavioral change augments the drug; it does not replace it.
- Anyone restarting a GLP-1 after a long gap should do so under clinical supervision, as restart protocols, including dose titration, vary and unsupervised restarts carry gastrointestinal risk.
- PCOS, which she tags but does not discuss, is associated with insulin resistance. GLP-1 medications have shown metabolic benefit in PCOS populations in small trials, but this is not an approved indication.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
LizDamyl · TikTok creator
82.5K views on this video
Lets get back to it!! #weightloss #weightlossjourney #pcos #glp1
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by LizDamyl, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.